Good afternoon, welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech and specialty pharma analyst here at Jefferies. I have the wonderful pleasure of having John Shannon and Josh Bennett here from Xeris. Welcome.
Thank you.
Thank you, Dennis.
Maybe to level set everybody, just give us a bit of background around Xeris, and we'll certainly talk about RECORLEV, but just talk about all the progress you guys have made this year.
Xeris is a fast-growing biopharma company. We just raised our guidance with our third quarter earnings to $395 million-$405 million this year. That is 37% growth at the midpoint. We have been carrying that type of growth. It is driven by three products, RECORLEV, which I am sure we are going to talk a lot about for Cushing's, GVOKE, which is basically an EpiPen for diabetics for hypoglycemia, and then KEVEYIS, which is our ultra-rare product for primary periodic paralysis.
Those three products with their growth trajectory, we also, at the start of this quarter, we changed our, we put our 2030 outlook. We raised that from just a year and a half ago, we set that at $750 million. We have now raised that to over $1 billion by 2030 with those three products. And then we have one more product in development. We are about to start the phase III program there, which is XP-8121, which is a once-weekly subcutaneous product for levothyroxine. I will stop there, and I know you got a lot of questions.
I mean, why do not we get started with RECORLEV? I mean, the magnitude of growth has been really impressive, and I know you guys essentially doubled your sales force at the beginning of the year. Talk about how that has gone and talk about also demand and just where that has shaken out.
RECORLEV is our growth engine for the company. We doubled our commercial footprint in January. It is our third expansion since we launched this product in 2022. It was a very significant expansion for us. As we look at this marketplace and the opportunity here, there is tremendous growth in more and more people being screened and detected for hypercortisolism, specifically in areas where there is resistant disease. So resistant diabetes, resistant hypertension, resistant obesity. The drugs they are on are not working, and therefore, when you look and find cortisol levels two times above the upper limit of normal, that is usually what the clinicians are looking for, you have found the culprit. There is a lot of movement in this space where more and more clinicians are testing for these patients. RECORLEV is benefiting from that information in the marketplace.
There is data now that supports that. Guidelines have recently changed with ADA and EASD, and those are driving even more and more people to screen and detect and driving our growth. Adding our sales organization and expanding them really allows us to get to and scale with the growth in this marketplace, and that really contributed to us really putting RECORLEV on a different growth trend in the third quarter. Generally, it would take six to nine months. We saw it come faster and a little more aggressive. That is why we changed a lot of our led to a lot of changes of our longer-term trajectory was because of the RECORLEV being on a new growth trend that now we think will get us to a billion-dollar product in three to four years sooner than we said before, which was 2035.
Can you give a little bit more color as to the guideline updates and what do guidelines say specifically, and how are you guys capitalizing on that?
Specifically, the guidelines talk about when you, in the case of diabetes, for example, they say if you have resistant diabetes, the insulin is not working, then you should test for cortisol levels. The guidelines basically all point to if you are 1.8 times above the upper limit of normal, then you should treat that cortisol level. Because what we find is when you bring the cortisol levels back to normal range, then the insulin works and other drugs work. So the guidelines are really important because it really helps the next level of primary care. Now, the endocrinologists have been doing this for a couple years now, but now this really opens up other categories, specifically primary care physicians who now have not only the medical guidelines are clear here, but now they have got guidelines all the way down to ADA and EASD.
When your sales reps are out in the field, are they seeing that broadening prescriber base beyond the specialists and into the PCPs?
Yes, that's exactly what's happening. When we do our expansions, there's two things that happen. One is you find more patients within the existing prescribers, but you're finding more targets. That's really what's happening in this space for all three products in this category. Everybody's finding more prescribers as more and more people are testing and screening for cortisol levels.
Okay. Can you comment a little bit about persistence and how long patients are on RECORLEV, and typically by the time they get RECORLEV, have they failed other therapies or have they just been newly diagnosed?
Yeah. Let's start with the majority of the patients that are coming on RECORLEV, more than 60% of them are new news, never been on a medical therapy. There's less and less switching in this space, but most of them are coming as new news, so first time on therapy. Then in terms of persistence, we watch that trend line, but it's not going to change much with so many people new to therapy. The challenge with this space is these are very complex patients to treat, multiple comorbidities. Especially over the first three to four months, people will drop out because a couple things. One is you get cortisol withdrawal. You feel good with cortisol, and you pull that away and start getting in a normal range, people feel that. Plus, you're adjusting all their other meds.
Their hypertensive agents, their diabetes, everything you can imagine that they are on needs to be adjusted when cortisol levels get in normal. There is a lot of If you get through the first three or four months, people will be fine and forever. We have people that have been on RECORLEV for 10 years. You just got to get through those first three to four months in this space, and then hang in there. But we watch our persistence, we watch conversion rates, all those things, and we just keep the trend lines pretty flat when we are adding so many new patients every month, every week, every quarter, that those trend lines are going to hold pretty steady for some time.
Sure. Okay. On third quarter earnings call, you guys raised new guidance, not only pulling forward RECORLEV $1 billion by a couple years, but also $1 billion in total revenue in 2030. Can you talk about why now, the timing of such? What have you seen that really gives you confidence to bridge where RECORLEV is today, which is around $225 million-$250 million, to $1 billion?
Yeah, let's start with, first of all, I was getting this question back in late summer. "Wait, your numbers seem like you're going to hit that 750." We knew we were going to have to adjust it. What we really were waiting to see, one is, where the new sales force expansion on RECORLEV kicking in, and we saw that in the third quarter. RECORLEV did over $71 million in the third quarter, and that puts us on a very different trajectory than we were in the first half of the year, which we anticipated, but it was a little better than even we expected. That trajectory first starts that. Then we add onto it, our other two products are both in growth modes again.
GVOKE moved back into a growth mode, so we think that's another product that's going to grow indefinitely, high single digit to maybe low double-digit growth for years to come. KEVEYIS, which had been pretty flat and steady, we put that on a growth curve as well. We've made some investments in the early start of the fourth quarter to even drive even more growth there and finding more patients. With all three products growing and RECORLEV on a new trajectory, we had to move our 2030 outlook up to more than $1 billion.
Sure. When I take a step back and look at all three products in Cushing's today, they are all seeing tremendous amount of growth. How should investors think about access, and at what point do you think payers will catch on and start putting in additional restriction? We cover a lot of companies, and that has seemed to be a dynamic that occurs earlier than what other management teams have thought about.
Yeah, we haven't seen it yet. Will we see it in the future? I don't know. I will tell you this category is all prior authorization, medical necessity. Every product has to go through that. There's not a lot of opportunity to go and buy access with payers. You have to get each patient based on the medical need and medical necessity. In those scenarios, payers are It's hard for them to play in that space.
W e haven't seen it yet. I don't know that we'll see it. This is still a rare disease. Even when we look at the top end of the range, maybe 40,000-50,000 patients out there. So, I'm not sure it's that big of a payer issue longer term. We also know that there's significant improvement in multiple comorbidities in this space, which again, is what everybody's trying to do, both at the clinician level and in many cases, the payers.
Okay. If you think about next year, can you help give us sort of bookends without it being guidance bookends in terms of like how we should think about RECORLEV growth, especially after the sales force expansion?
Yes. RECORLEV's on a new trajectory. You can look at that and map that out. It's pretty obvious what RECORLEV will be able to do if you just look at the performance in the third quarter, and what we've guided to for the rest of the year.
That's clear. We see all three products growing next year. A dd in another 9%, 10% for GVOKE, add in some growth for KEVEYIS, and that can give you some bookends. All of them track towards us having a significant growth year next year, just like we did this year.
Okay. If we look at RECORLEV in Q3, that was around $70 million, $71 million. You annualize that because you are at $280 million, and then you apply some level of continued growth in 2027. So, that kind of gets you to around a $350 million number, using my back of the envelope math. Do you think that is sort of a reasonable ballpark of what people should be expecting next year?
Or better.
Or better? Okay, perfect. Can we talk a little bit about GVOKE? Just, that product has been approved for a while. How are you seeing revenue growth over the next three to five years?
Yeah. GVOKE is an area where there's 15 million people today that, based on the medical guidelines, should have a ready-to-use glucagon just in case they go low. We estimate that less than a million today have a GVOKE ready, or any kind of ready-to-use glucagon out there. There's lots of opportunity to not only educate about the guidelines, but also, you really have to change practice with these clinicians, because they've never had anything in the past.
It's a lot of effort to get them to adjust how they do and run their practice around their diabetes patients, and making sure that if you're on these products, you have one of these just in case. Please make sure you pick it up. That's an effort where we're starting to find more and more traction as we go here. You can see that in the weekly prescriptions. The market's back to growing for the last couple quarters, and we're capturing more than our fair share of the market.
When I think about the penetration of these glucagon products, they have been way lower than what you would expect. I understand that changing physician behavior may take a little bit of time. What efforts are you taking, maybe you and some of your competitors in the space, what efforts are you guys taking to really accelerate that? When I think about GVOKE, maybe it's like a mid-high single-digit grower, but how do you accelerate that?
Yeah. That's a challenge because, typical endocrinologist or somebody, a diabetologist, is a very busy person. They're so focused on getting the insulin and getting the blood sugar in order that they, in many cases, forget to even mention that, "B y the way, you should have one of these just in case." So, putting it into their practice is the game for us. Making sure it's flagged on their records, making sure it's put into their guidelines and protocols within the office, and then reassuring to the patient, "Hey, don't forget to pick this up when."
Because they'll get there to the pharmacy, and if the physician didn't tell them, "B y the way, you need to grab this," they'll be like, "I didn't order that. Why do I need that?" All of that needs to be systematically changed, and that's a lot of what our team works on with the clinicians, with the offices, to help them kind of implement the standard that you have to change within the practice.
Got it. What about KEVEYIS? How should we think about that? You just talked about making some investments to return that back to growth. What are some of those investments?
Yeah, KEVEYIS is my favorite product. It's one of those products where what you do for the product in terms of patient support and things like that is as important, sometimes even more important than the medicine itself. So, this is one of those scenarios where we continue to build. We find the patients with KEVEYIS.
That's the first and foremost. Second, we walk into a doctor's office and say, "You have someone like this, and this. You might have a PPP patient. Do you know who that is?" We have to start with explaining what PPP is, and then how do we treat that patient, right? Then supporting that along the way. So, we've made some incremental investments just in the last several weeks to put more field personnel out in the field to find these patients. There's probably 4,000 - 5,000 of them out there, and there's plenty to go find. We feel like we've got good capabilities in terms of figuring out how to find them, and then get in there and get them on therapy.
Perfect. Maybe in the last eight or nine minutes, we can shift over to your phase III program in hypothyroidism. So, talk a little bit about the rationale there, and when do you think you can start the phase III?
I'll let Josh go.
Sure. W e've developed, as John said, a once-weekly therapy for patients with hypothyroidism, and there are 22 million people treated on therapy today. We're focused on a subset. We're focused on what we estimate to be 3 million - 5 million patients who are unable to meet their treatment goals, primarily because of issues absorbing the only thing they have available today, which is oral therapy. We're on the verge of starting our phase III.
We'll initiate it by the end of the year, and are very confident in our product's ability to meet this unmet need. We hear consistently from our physicians, KOLs, a very high level of enthusiasm for it. In fact, we were at the American Thyroid Association meeting just a couple weeks ago, and were encouraged that multiple scientific sessions, KOLs, independent of our efforts, decided to highlight XP-8121 as an exciting development that they're eager to see come to market.
Okay. You guys disclosed a pretty robust registrational package with multiple studies. Maybe give a little bit more info around that and which study to really focus on, which one is really key to getting FDA approval.
Yeah, absolutely. We are very aligned with the agency on the study design, and KOLs are enthusiastic, and practicing physicians are enthusiastic. That has led to pillar one of our study design, which is a non-inferiority trial, which will secure approval, and we expect to secure approval. Physicians have told us, because they are familiar with the API, it gives them everything they need to start writing the drug. Because we also have to bolster our package to maximize the opportunity, and to make sure we have got a robust data package for payers, there are two other kind of pillars to our program. One is that we will also initiate next year a special population study in patients who are poorly controlled on oral levothyroxine, convert them to XP-8121, and show that we can resolve persistent lack of control.
The final piece is we are investing heavily in real-world evidence generation. This space has seen no innovation or minimal innovation for 40 years. There is not a lot of data, so we have an opportunity and an obligation to bring the unmet need to life. At this same ATA meeting, we published for the first time some of these data, and what was really compelling to us is we have consistently believed that among the 22 million patients, 20% of them are appropriate candidates.
What we found in our analysis is actually among the patients we looked at, 25% of them were out of range twice in a one-year period, which is striking because most patients only get tested once a year, means in consecutive tests they were out of range. We are seeing increasing data that the unmet need is very significant and persistent, and we have the opportunity pre-launch to really characterize that and bring it to life.
The phase III, I believe, is called Cornerstone?
That's right.
That's the non-inferiority. Maybe talk about the design of that and why you guys selected non-inferiority as the endpoint?
Yeah, I think, so Cornerstone is a comparative non-inferiority trial versus the standard of care, which is oral levothyroxine, specifically Synthroid. We'll study 500 participants, randomize them one-to-one, and success is going to be the percentage of patients who have normal TSH at the end of the study, measured in the last two treatment periods, which are weeks 48 and 54. Why did we choose non-inferiority? I think it's based on the feedback from the FDA and the feedback from physicians, said, "We need this, and we want the highest probability path to approval." Cornerstone gives us what we believe is a very high probability path of approval. But we didn't want to stop there, which is why also Touchstone, our special population study, and our Capstone pediatric study, as well as real-world evidence, are part of the total program.
Got it. Okay, I understand what you're saying about trying to maximize the probability of success. I'm assuming that based off of your prior PK work and PK/PD phase I, phase II study, that you feel pretty confident that you should be within the range, that you should be non-inferior. Is there a scenario where you can actually achieve superiority?
Yeah, I think that we are if we achieve non-inferiority, we believe we can, with high confidence, we'll hit the $1 billion-$3 billion peak sales that we have said are possible with XP-8121. There is the opportunity to demonstrate superiority, both on the primary endpoint as well as some of our key secondary endpoints, which include measuring the proportion of time that patients are in range on key biochemical measures in the last six months of the study. We're not counting on that, but we do think we have the opportunity to do that, and that would only add to the data package, potentially add to the potential of the product.
Okay. How are you thinking about access once you guys get approved on a non-inferiority phase III?
Yeah, it's a great question because the KOL and physician enthusiasm is so high that it lets us really focus on access. I think what it starts with is just to frame this. We're focused on the highest unmet need. We hear this all the time. There are patients that just cannot get into range, and that leaves them with significant long-term morbidity. It's very well understood, it's very accepted, and the guidelines are clear. You have to get people into range. Given that, we've built this integrated data package, but also, we're focused just on these patients. Of the 3 million-5 million, we can achieve our goals with no more than 10% of that population. By focusing on the highest unmet need, we believe the payers will be able to grant the access we need to power through.
Most importantly, just like John was talking about for RECORLEV, every single patient will require prior authorization. They will require failure on oral, but they are already treated on oral today. The failure is already in the chart. We do not need to, we do not believe, initiate a new therapy. We just need to find the millions of patients that have demonstrated inability to achieve biochemical control and use that existing data for the prior authorization. The payers, at the end of the day, this is a patient who has been demonstrated not to meet the guidelines, where no other option will have demonstrated that they can help them get into range.
Right. Just help me understand, because the phase III, I believe both the primary and also the secondaries, they are all being measured for non-inferiority ?
The secondaries will be measured for superiority and will allow for that. But it is the combination of the non-inferiority study to prove for well-controlled patients, as well as the real-world evidence and the special population study, in total, we believe will ensure the access we need.
When will you guys disclose the data?
Yeah, so we are targeting top line by the end of 2028.
Okay. Do you have a sense on pricing so far?
Yeah, I think that we're not, it's a little early. We're targeting approval in 2030, four years away probably to guide on price. But I think when you look at what we've said, which is $1 billion-$3 billion peak sales- And needing only 10% of the population, I think can help understand maybe the bumpers in which we might fit. What I will say is we think our price assumptions are conservative and achievable.
Perfect. Maybe in the last minute, just remind us, your cash, your debt, and then also maybe even BD, right? I know there's so many things happening, and they're all going the right direction, but what about-
All is good. We became profitable a little over a year ago, we continue to stay profitable. We continue to invest for more and more growth, including our existing products and our pipeline. Then our next priority becomes, what do we do with the rest of the cash we're generating as we go forward? Because again, we have 88% gross margins, growing, getting better each quarter. So we look down the BD line, and maybe Josh, you can talk a little bit about some of the things you're looking at?
Sure, BD is really the next frontier for us now that we have both the cash and the balance sheet capacity to be more aggressive. We're really focused on things that leverage our strengths, right? First and foremost, we have an incredible commercial engine, and the commercial engine is proven in ultra-rare, rare, and general endocrinology. So we think it's flexible enough to look at a lot of assets that may fit across rare and endocrinology. Ideally, we're targeting things that contribute revenue and growth in the next three to six years before XP-8121 becomes very material to the P&L. But at the same time, we don't need to do BD. We would like to. So we're going to be disciplined and make sure that what we do is something we can execute on, just as we always try to do is meet our expectations.
Perfect. I think that's all the time that we have today. Thanks so much for being here.
Thank you.
It's great to see you guys.
Thanks for having us.
Thanks.